Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
– Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis
-RemeGen receives initial payment of $125 million consisting of an upfront payment of $45 million plus $80 million of warrants, potential regulatory and commercial milestones exceeding $4 billion, as well as tiered royalties
-Seasoned biopharma leader, Jean-Paul Kress, MD, appointed as Chief Executive Officer and Chairman of the Board, bringing proven track record in clinical development, commercialization, and strategic growth
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Vor Bio, Inc. (Nasdaq: VOR) and RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331) today announced entry into an exclusive license agreement granting Vor Bio global rights (excluding China, Hong Kong, Macau and Taiwan) to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Under the terms of the agreement, Vor Bio will pay RemeGen an initial payment of $125 million consisting of an upfront payment of $45 million as well as $80 million of warrants to purchase common stock with an exercise price of $0.0001 per share. The agreement also provides for potential regulatory and commercial milestones exceeding $4 billion, in addition to tiered royalties.
Telitacicept is a novel, investigational fusion protein that targets key immune pathways involved in autoimmune disease. By selectively inhibiting BlyS (also known as BAFF) and APRIL – cytokines critical to B cell survival – telitacicept reduces autoreactive B cells and autoantibody production. RemeGen is conducting a global Phase 3 clinical trial which is now enrolling in the United States, Europe, and South America, with initial results expected in the first half of 2027.
Vor Bio also announced that its Board of Directors (the 'Board') has appointed Jean-Paul Kress, M.D., as Chief Executive Officer and Chairman of the Board, effective today. This follows Dr. Robert Ang's resignation from the positions of Chief Executive Officer and director earlier today. Dr. Ang will continue with Vor Bio as a strategic advisor to assist in the transition through October 2025. Dr. Kress's strategic vision and track record of transformative leadership position him to guide the company into its next phase of growth.
'I am absolutely thrilled to be leading Vor Bio as we transform the company to become a major player in autoimmune disease treatment,' said Dr. Kress, Chairman and Chief Executive Officer, Vor Bio. 'Targeting BAFF/APRIL signaling with telitacicept represents a significant advancement in addressing autoantibody driven diseases, which is highly differentiated from other modalities in this space. With a clinically advanced asset, we are uniquely positioned to develop this innovative therapy, with the goal of making a meaningful impact for patients living with autoimmune diseases around the world.'
Dr. Kress brings decades of executive leadership experience in the pharmaceutical and biotech industries. He most recently served as Chief Executive Officer of MorphoSys, where he led the development, approval and commercialization of Monjuvi®️ (tafasitamab), and advanced the company's pipeline through the landmark acquisition of Constellation Pharmaceuticals in 2021, strengthening MorphoSys' position in oncology innovation and ultimately leading to its subsequent acquisition by Novartis in 2024. Prior to that, he was CEO of Syntimmune, guiding its lead immunology program through to acquisition by Alexion Pharmaceuticals. He currently serves on the Board of Sanofi S.A. and has held senior roles across leading biopharma companies.
'Today marks a transformative milestone for RemeGen and the global development of telitacicept,' said Dr. Jianmin Fang, CEO of RemeGen. 'The strategic out-licensing of telitacicept's ex-China rights accelerates our mission to deliver this innovative therapy to patients worldwide and will help maximize telitacicept's clinical and commercial potential on the global scale.'
About Telitacicept
Telitacicept is a novel, investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL – two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. In a Phase 3 clinical trial in generalized myasthenia gravis in China, telitacicept demonstrated a 4.8-point improvement in MG-ADL (Myasthenia Gravis Activities of Daily Living scale) vs. placebo at 24 weeks, the primary endpoint of the trial.
Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
About RemeGen Co. Ltd.
Founded in 2008, RemeGen is a leading biopharmaceutical company in China committed to providing solutions to the unmet clinical needs of patients suffering from life-threatening illnesses. RemeGen has research laboratories and offices in China and the United States. The company is committed to discovering, developing, and commercializing innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune, oncology, and ophthalmic diseases.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words 'aim,' 'anticipate,' 'can,' 'continue,' 'could,' 'design,' 'enable,' 'expect,' 'initiate,' 'intend,' 'may,' 'on-track,' 'ongoing,' 'plan,' 'potential,' 'should,' 'target,' 'update,' 'will,' 'would,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio's statements regarding its plans for development and commercialization of telitacicept, the potential of telitacicept in various indications, the timing and pace of patient enrollment and dosing in clinical trials and the availability of data therefrom, the expected safety profile of telitacicept, the market opportunities for telitacicept and the ability of telitacicept to transform patient lives. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Vor Bio's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; uncertainties regarding regulatory approvals to conduct trials or to market products; and availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements and Vor Bio's ability to continue as a going concern. These and other risks are described in greater detail under the caption 'Risk Factors' included in Vor Bio's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Contact:Investors & MediaSarah Spencer +1 857-242-6076
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Stock market today: Dow, S&P 500 and Nasdaq futures rise as stocks set to end June with a bang
US stock futures edged higher Sunday evening, setting up the major indexes for more records to end one of the most volatile first halves of a year in recent memory. Futures tied to the Dow Jones Industrial Average (YM=F) rose around 0.5%. Contracts on the S&P 500 (ES=F) gained 0.2%, and Nasdaq 100 (NQ=F) futures ticked up 0.3%. Several of Trump's economic agenda items are in focus this week. A July 9 deadline looms before the possible resumption of Trump's unilateral tariffs, which Trump on Sunday said he didn't think he'd "need to" extend. On the trade front, India has extended its Washington visit to finalize a deal. Administration officials last week confirmed a trade framework with China was in place, bolstering investor sentiment despite a late-Friday dip triggered by Trump's abrupt halt to talks with Canada, citing its digital tax policy. Meanwhile, market watchers are closely following Senate negotiations over Trump's proposed $4.5 trillion tax cut bill. The measure, which passed a procedural vote Saturday, could face a tough path in the House. The Congressional Budget Office estimates it would add $3.3 trillion to the deficit over a decade. For the market, June's gains have been substantial, fueled by optimism surrounding global trade and easing fears over tariffs. The S&P 500 (^GSPC) is up over 4%, the Nasdaq Composite (^IXIC) has surged over 5.5%, and the Dow (^DJI) has climbed 3.5%. On Friday, all three major indexes closed higher, with the S&P and Nasdaq reaching new record highs for the first time since February — the start of the year's tariff-fueled stock swings. All three major indexes are up at least 3% so far this year. Looking ahead, investors will monitor key Chinese PMI data due Monday to gauge how the ongoing trade war is affecting Asia's largest economy. Despite lingering uncertainties, the broader market remains upbeat heading into the new quarter and second half.
Yahoo
an hour ago
- Yahoo
Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements
DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ('Portage' or the 'Company') (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands ('Portage'), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. About Portage BiotechPortage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to transform the immune system's ability to fight cancer. For more information, visit Forward-Looking StatementsAll statements in this news release, other than statements of historical facts, including without limitation, statements regarding the Company's business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or that otherwise include the words 'believe,' 'expects,' 'anticipates,' 'intends,' 'estimates,' 'will,' 'may,' 'plans,' 'potential,' 'continues,' or similar expressions or variations on such expressions are forward-looking statements. As a result, forward-looking statements are subject to certain risks and uncertainties, including, but not limited to: the risk that the Company may not secure financing, the uncertainty of the Company's ability to continue as a going concern, scientific results may not be as expected, and other factors set forth in 'Item 3 - Key Information-Risk Factors' in the Company's Annual Report on Form 20-F for the year ended March 31, 2024 and 'Business Environment – Risk Factors' in the Company's Management's Discussion and Analysis for the Three and Six Months ended September 30, 2024, filed as Exhibit 99.2 to the Company's Form 6-K. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law. For More Information:Portage BiotechAlexander Pickett, Chief Executive Officerir@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
Is Tesla Stock a Millionaire Maker?
In the past 15 years, this top EV stock has climbed more than 20,000%. Tesla shares have always sold for a premium, which is detached from the reality of the current business. Investors considering buying the stock must believe the company will make good on its plans for autonomous driving and robotics. These 10 stocks could mint the next wave of millionaires › Looking back at its history as a public company, Tesla (NASDAQ: TSLA) has generated serious wealth for investors. The auto industry disruptor has seen its shares skyrocket 20,290% since its initial public offering in June 2010 (as of June 25). Had you invested just $5,000 back then, there would be a $1 million balance in your portfolio right now. No one would argue with that kind of impressive past gain. But will the leading EV stock be a millionaire maker in the future? Tesla might be the most closely watched business in the world, partly, because of how it disrupted the global car market. Investors also keep tabs on what CEO Elon Musk is doing, as well as his plans for the company (more on this below). However, investors shouldn't lose sight of what Tesla really is today, which is a challenged company that sells innovative and tech-enhanced EVs. In the first quarter, the business reported $14 billion of automotive revenue, 72% of the total. Total revenue was up just 0.9% in 2024, then it declined 9.2% in Q1 2025. Operating income in the first quarter tanked 66%, thanks to lower average selling prices, fewer deliveries, and higher expenses. To be fair, this is an extremely inventive company that's working at the cutting edge of exciting technologies. But someone viewing Tesla with a clear lens would see that this is a struggling business. Its core operations are under pressure, without a doubt. What valuation should Tesla trade at knowing the reality of the business today? Even with a more reasonable price-to-earnings ratio (P/E) of 50 (compared to its current P/E ratio of 179), which is what luxury automaker Ferrari trades for, the stock has 72% downside. That certainly doesn't give investors any reason to be bullish. Based on the current market cap of $1 trillion and P/E ratio of 179, Tesla is wildly overvalued. But the story stock has seemingly always traded at a steep valuation, as investors continue to bet on a future that sees the company realizing its potential as a dominant force in autonomous driving and robotics. The company has finally launched a robotaxi service in Austin, Texas. This was highly anticipated and something that Musk has talked about for years. However, I think it turned out to be a big nothing burger. There were no Cybercabs. Less than two dozen Model Ys were used instead. There were human supervisors in all the vehicles. And videos of the robotaxis in action showed numerous issues, spurring an investigation by the National Highway Traffic Safety Administration. At the same time, Alphabet's Waymo is handling 250,000 trips per week in multiple cities. And an application is in place to start testing the service in New York City. Tesla appears to still have a long way to go. The company is also leveraging its AI capabilities to work on Optimus, a humanoid robot. Musk believes it will produce 1 million units annually by the end of this decade. Besides placing these machines in its factories, the goal is to sell them to other companies. If all goes according to plan, which is a very uncertain outcome, then Tesla could make its investors into millionaires down the road. The end markets for robotaxis and humanoid robots are estimated to be measured in the trillions of dollars. The company's ability to not only have these technologies achieve mass adoption, but to also capture a sizable chunk of the opportunity, could create a financial windfall. However, I think there's also a good chance that the business won't deliver up to its heightened expectations, a perspective that's supported by a history of constant delays. This is a stock that I'm still avoiding. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $409,114!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $38,173!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $713,547!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 23, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet and Tesla. The Motley Fool has a disclosure policy. Is Tesla Stock a Millionaire Maker? was originally published by The Motley Fool
